Advisory Research’s Acceleron Pharma XLRN Stock Holding History

Advisory Research’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,230	Closed	-$980K	–	428
2021 Q1	$980K	Sell	7,230 -248	-3%	-$32K	0.07%	209
2020 Q4	$957K	Sell	7,478 -2,017	-21%	-$236K	0.07%	198
2020 Q3	$1.07M	Sell	9,495 -805	-8%	-$80.1K	0.1%	168
2020 Q2	$981K	Buy	10,300 +1,941	+23%	+$187K	0.09%	171
2020 Q1	$751K	Buy	+8,359	New	+$650K	0.05%	153
2019 Q1	–	Sell	-17,988	Closed	-$783K	–	390
2018 Q4	$783K	Sell	17,988 -16,772	-48%	-$838K	0.02%	259
2018 Q3	$1.99M	Buy	34,760 +10,494	+43%	+$516K	0.03%	200
2018 Q2	$1.18M	Buy	+24,266	New	+$884K	0.02%	259
2017 Q1	–	Sell	-30,481	Closed	-$778K	–	428
2016 Q4	$778K	Buy	+30,481	New	+$966K	0.01%	298

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Advisory Research's XLRN Position: Q2 2021 in Review

Advisory Research sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 7,230 shares — an estimated $980K sold.

Advisory Research first reported a position in XLRN in Q4 2016 and held it in 9 quarters. The position peaked at $1.99M in Q3 2018. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

Advisory Research reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
Advisory Research sold 7,230 Acceleron Pharma shares in Q2 2021, an estimated $980K.
Advisory Research first reported a position in Acceleron Pharma in Q4 2016 and held it in 9 quarters.
Advisory Research's Acceleron Pharma position peaked at $1.99M in Q3 2018.
271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Advisory Research's 13F filing for Q2 2021, filed 16 Aug 2021.